{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:06:49Z","timestamp":1753877209884,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided P\u2009=\u2009.02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies.<\/jats:p>","DOI":"10.1093\/jncics\/pkaa111","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T06:22:37Z","timestamp":1607754157000},"source":"Crossref","is-referenced-by-count":1,"title":["Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort"],"prefix":"10.1093","volume":"5","author":[{"given":"Elizabeth B","family":"Lamont","sequence":"first","affiliation":[{"name":"COTA, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Yee","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart L","family":"Goldberg","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D","family":"Norden","sequence":"additional","affiliation":[{"name":"COTA, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"issue":"4117","key":"2021010806513119300_pkaa111-B1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1126\/science.182.4117.1102","article-title":"Small area variations in health care delivery","volume":"182","author":"Wenneberg","year":"1973","journal-title":"Science"},{"issue":"14","key":"2021010806513119300_pkaa111-B2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"issue":"26","key":"2021010806513119300_pkaa111-B3","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021010806513119300_pkaa111-B4"},{"issue":"12","key":"2021010806513119300_pkaa111-B5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain in chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"2021010806513119300_pkaa111-B6","doi-asserted-by":"crossref","first-page":"E113","DOI":"10.1016\/j.clml.2015.07.292","article-title":"Multiple myeloma as a second primary malignancy; one fourth of patients had prior history of other malignancies","volume":"15","author":"Nishimura","year":"2015","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"6","key":"2021010806513119300_pkaa111-B7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.anndiagpath.2011.04.010","article-title":"A patient with prostate cancer and multiple myeloma\u2014diagnostics and possible association of both diseases","volume":"16","author":"Su\u010di\u0107","year":"2012","journal-title":"Ann Diagn Pathol"},{"issue":"4","key":"2021010806513119300_pkaa111-B8","doi-asserted-by":"crossref","first-page":"970.e15-970","DOI":"10.1016\/j.urology.2011.05.035","article-title":"Prostate cancer risk alleles and their associations with other malignancies","volume":"78","author":"Cooper","year":"2011","journal-title":"Urology"},{"issue":"13","key":"2021010806513119300_pkaa111-B9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/89.13.955","article-title":"Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study","volume":"8989","author":"Cooney","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"2-4","key":"2021010806513119300_pkaa111-B10","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000108316","article-title":"Genetics and epigenetics of 1q rearrangements in hematological malignancies","volume":"118","author":"Fournier","year":"2007","journal-title":"Cytogenet Genome Res"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaa111\/35387310\/pkaa111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/5\/1\/pkaa111\/35530468\/pkaa111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jncics\/article-pdf\/5\/1\/pkaa111\/35530468\/pkaa111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T22:04:15Z","timestamp":1610575455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaa111\/6062405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaa111","relation":{},"ISSN":["2515-5091"],"issn-type":[{"type":"electronic","value":"2515-5091"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2021,1,4]]},"article-number":"pkaa111"}}